Mohsen A. Hedaya

Dr. Mohsen A. Hedaya

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
BABashaier Mohammed Al-Kandari
Bashaier Mohammed Al-Kandari
MAMonerah H. Al-Soraj
Monerah H. Al-Soraj
MHMohsen A. Hedaya
Mohsen A. Hedaya

19 September 2023 in Pharmacy
Verified
Journal Article
Open access
PDF file
AMAdel M.Chakroun
Adel M.Chakroun
MQMohammad Qaddoumi
Mohammad Qaddoumi
DADalal M. Al-Taweel
Dalal M. Al-Taweel
SASarah Alghanem
Sarah Alghanem
Tania BayoudTania Bayoud
Tania Bayoud
DADanah Alsane
Danah Alsane
The development of competency frameworks serves as the foundation for the development of competency-based education. It is vital to develop a country-specific framework to address the specific needs of the local population for pharmacy services. This study aimed to describe the development process of a competency framework for undergraduate pharmacy education in Kuwait with a unique matrix structure. The process started with the development of guiding principles for curriculum revision and implementation, as well as the identification of global educational outcomes. This process was followed by: (A) a needs assessment with key stakeholders; (B) development of the initial competency framework; and (C) refinement of the framework. Qualitative data were thematically analyzed to identify the main competency domains that students need to perform the identified entrustable professional activities (EPAs). Five population needs were identified by the needs assessment, with 17 EPAs suggested to fulfill those needs. In addition, 11 competency domains were identified. The initial competency framework was created as a 3 × 8 matrix, with 3 professional and 8 transversal competency domains. Refinement of the framework resulted in the removal of redundancies and the development of a global behavior competency profile. The development of a matrix competency framework and associated EPAs for Kuwait serves as a foundation for preparing pharmacists to fulfill local population needs and expanding the scope of practice in the country.

17 July 2023
Verified
Book
Closed access
PDF file
MHMohsen A. Hedaya
Mohsen A. Hedaya
This book introduces basic pharmacokinetic concepts to beginner learners to help them understand the absorption, distribution, metabolism, and excretion of drugs. After a basic introduction to pharmacokinetics and its related fields, the book provides a clear introduction to quantitative pharmacokinetic relations and the interplay between pharmacokinetic parameters after different routes of drug administration. Emphasizing the application and importance of pharmacokinetic concepts in clinical practice throughout, the book features: A clear, simple, and concise style with the use of graphs and simulations to aid learning. Bullet point summaries of each concept to demonstrate applications in clinical practice. Practice problems and solved examples to help the reader understand the best approach for calculating pharmacokinetic parameters. A glossary of key words and acronyms. This book is an essential read for undergraduate and graduate pharmacokinetic students in pharmacy, pharmacology, and pharmaceutical science programs worldwide. Accompanying the book is a website with self-instructional tutorials and pharmacokinetic simulations, allowing visualization of concepts for enhanced comprehension. This learning tool received an award from the American Association of Colleges of Pharmacy for innovation in teaching, making it a valuable supplement to this textbook.

17 July 2023
Verified
Book Chapter
Closed access
MHMohsen A. Hedaya
Mohsen A. Hedaya
Drugs administered orally are absorbed into the systemic circulation to produce their systemic effects. The rate of drug absorption affects the rate at which the drug appears in the systemic circulation, which has been correlated with the onset of drug effects. The absorption rate constant is the pharmacokinetic parameter that quantitatively describes the rate of drug absorption that encompasses the steps included in drug absorption such as disintegration, dissolution, and permeation of drugs after administration of solid dosage forms. Rapid drug absorption is usually required when immediate drug effect is needed such as in case of treating acute symptoms and in case of emergency. However, rapid drug absorption is not always advantageous, because during multiple drug administration for the management of chronic diseases, the use of slowly absorbed dosage forms is preferred to produce a steady therapeutic effect. So, determination of the drug absorption rate after administration of different products for the same active drug is important. The rate of drug absorption from different products can be evaluated by comparing the time when the maximum plasma drug concentration is achieved after administration of the different products and also by comparing the absorption rate constants determined after administration of the different products.

1 December 2021 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MHMohsen A. Hedaya
Mohsen A. Hedaya
SMsoha el masry
soha el masry
SHSally Helmy
Sally Helmy

28 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MHMohsen A. Hedaya
Mohsen A. Hedaya
OPOludotun Adebayo Phillips
Oludotun Adebayo Phillips
VTVidhya Thomas
Vidhya Thomas
MQMohammad Qaddoumi
Mohammad Qaddoumi
SKSamuel Binamin Kombian
Samuel Binamin Kombian
NANaser Altannak
Naser Altannak
Background: We recently synthesized a novel series of triazolyl-oxazolidinones (PH066, PH139, PH162, and PH166) that exhibited significant in vivo anticonvulsant activity in rat models of electrically- and chemically-induced seizures. Objectives: The objectives of the current study were to develop and validate analytical UPLC-MS/MS assays for quantitative determination of these novel compounds in plasma and tissue samples obtained from pharmacokinetic studies to support and/or explain the reported in vivo effects in rats, as well as to study the stability of these compounds in the solid state. Methods: Sensitive, selective, precise, and accurate UPLC-MS/MS methods were developed using a UPLC BEH C18 column for analyte separation. The mobile phase consisted of water with 0.1% formic acid and acetonitrile with 0.1% formic acid in different ratios depending on the analyte of interest. Quantitative determination was performed using the multiple-reaction monitoring scanning mode. The methods were utilized to determine the concentration of the four compounds in plasma and tissue samples obtained at different time points after intraperitoneal (IP) injection of 100 mg/kg of each compound to rats. The stability of the compounds was investigated under forced degradation conditions. Results: The developed methods were specific for each of the analytes and were found to be linear in the concentration range of 5–30 μg/mL in plasma and 0.5–25 μg/g in tissue samples. The intra-day and inter-day precision and accuracies were within the acceptable range for the four compounds. The methods were applied to quantify these compounds in the plasma and various tissue samples obtained from rats after IP administration of 100 mg/kg of each compound. The maximum plasma concentrations were 14.6, 9.20, 14.5, and 18.1 μg/mL, and those of brain were 2.6, 0.22, 1.9, and 2.8 μg/g for PH066, PH139, PH162, and PH166, respectively. The compounds degraded under forced degradation conditions to various degradation products. Conclusions: The developed methods were selective, linear, accurate, and precise and are suitable for quantitation of the four compounds in plasma and tissue samples obtained during pharmacokinetic investigations, as well as for detecting and quantifying their degradation products.